Safety and Efficacy of Miglustat in Chinese NPC Patients
Status:
Active, not recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV
confirmatory study.
Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this
study. The study will be conducted at 2 sites in China.